ArticleInfectious diseases and therapy2022

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.

Giovanni Landoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.